Free Trial

Christopher Liu Analyst Performance

Analyst at Leerink Partners

Christopher Liu is a stock analyst at Leerink Partners in the medical sector, covering 7 publicly traded companies. Over the past year, Christopher Liu has issued 1 stock ratings, including and buy recommendations. While full access to Christopher Liu's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Christopher Liu's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
10 Last 8 Years
Buy Recommendations
70.00% 7 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy70.0%7 ratings
Hold30.0%3 ratings
Sell0.0%0 ratings

Out of 10 total stock ratings issued by Christopher Liu at Leerink Partners, the majority (70.0%) have been Buy recommendations, followed by 30.0% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
71.4% of companies on NASDAQ
5 companies
NYSE
28.6% of companies on NYSE
2 companies

Christopher Liu, an analyst at Leerink Partners, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Christopher Liu of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
42.9%
MED - GENERIC DRG
1 company
14.3%
MED - DRUGS
1 company
14.3%
MED PRODUCTS
1 company
14.3%
PHARMACEUTICAL PREPARATIONS
1 company
14.3%

Christopher Liu's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Exelixis, Inc. stock logo
EXEL
Exelixis
10/21/2025Upgrade$34.54$48.00Outperform